High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
Human genetics
DOI:
10.1186/s13073-022-01076-0
Publication Date:
2022-08-21T23:02:53Z
AUTHORS (91)
ABSTRACT
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains are a serious health problem in India, also contributing to one-fourth of the global MDR (TB) burden. About 36% MTBC reported fluoroquinolone (FQ) resistant leading high pre-extensively drug-resistant (pre-XDR) and XDR-TB (further resistance against bedaquiline and/or linezolid) rates. Still, factors driving MDR/pre-XDR epidemic India not well defined. In retrospective study, we analyzed 1852 consecutive obtained from patients tertiary care hospital laboratory Mumbai by whole genome sequencing (WGS). Univariate multivariate statistics was used investigate associated with pre-XDR. Core multi locus sequence typing, time scaled haplotypic density (THD) method homoplasy analysis were analyze epidemiological success, positive selection different strain groups, respectively. total, 1016 MDR, out which 703 (69.2%) pre-XDR 45 (4.4%) XDR. Cluster rates among (57.8%) pre-XDR/XDR (79%) three dominant L2 (Beijing) clusters (Cl 1-3) representing half 40% cases. pre-XDR/XDR-TB (P < 0.001) and, particularly Cl 1-3 strains, had first-line FQ (81.6-90.6%). Epidemic success using THD showed that outperformed L1, L3, L4 short- long-term scales. More importantly, + higher indices than their not-MDR counterparts. Overall, compensatory mutation highest detected genes drug tolerance (prpB ppsA) virulence (Rv2828c). Compensatory mutations threefold increase indices, suggesting improved transmissibility. Our data indicate drastic resistance, as emerging endangers newly endorsed MDR-TB treatment regimens. Rapid changes control strategies required contain transmission highly successful Metropolitan region but presumably India-wide.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (60)
CITATIONS (27)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....